What Happened?
Vancouver, BC-based Zymeworks Promoted John Fann as Senior Vice President of Process Sciences
Vancouver, BC-based Zymeworks Promoted John Fann as Senior Vice President of Process Sciences
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
John Fann is Senior Vice President of Process Sciences at Zymeworks. Previously, John held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Adams Mark, Shepherd Randy, Fairchild Troy, McGee Tim, wheatley don, Elfering David, Stallmer Todd, Simms Mark, Cheung Harry, Dean Erika, Alaei Esfandiar
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.